Assisted Reproductive Technology in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders (ARTiMS)
The purpose of this study is to improve the quality of care that women with Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD) receive while using Assisted Reproductive Technology (ART). We’re inviting women with MS or NMOSD who have already used ART to take part in surveys and interviews to discuss if and where […]
Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial
To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]
Australian MS Longitudinal Study
The Australian MS Longitudinal Study (AMSLS) is not a clinical trial. It is a survey-based study of life issues, designed to more fully understand the impact of MS, including the individual and overall community impacts. The data from the AMSLS provides a regularly updated, evidence base for a number of stakeholders including health professionals, scientific […]